Publications
Detailed Information
A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jin Won | - |
dc.contributor.author | Choi, In Sil | - |
dc.contributor.author | Kim, Yu Jung | - |
dc.contributor.author | Lee, Kyung-Hun | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Kim, Tae-Yong | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Lee, Jong Seok | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.date.accessioned | 2021-01-31T11:06:11Z | - |
dc.date.available | 2021-01-31T11:06:11Z | - |
dc.date.created | 2018-09-19 | - |
dc.date.created | 2018-09-19 | - |
dc.date.created | 2018-09-19 | - |
dc.date.created | 2018-09-19 | - |
dc.date.created | 2018-09-19 | - |
dc.date.created | 2018-09-19 | - |
dc.date.issued | 2015-06 | - |
dc.identifier.citation | Cancer Chemotherapy and Pharmacology, Vol.75 No.6, pp.1175-1182 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.other | 55301 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173025 | - |
dc.description.abstract | This is a phase I/II study of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with metastatic or recurrent gastric cancer. Phase I part with a standard 3 + 3 dose-escalation design was conducted to define the recommended phase II dose (RP2D) using four predefined dose levels of paclitaxel and irinotecan. The efficacy of RP2D was evaluated in a phase II part. In phase I part, 12 patients were enrolled. Dose-limiting toxicity was not observed. The RP2D was established as level 4 (paclitaxel-135 mg/m(2) and irinotecan-160 mg/m(2), every 3 weeks). In phase II part, 27 patients were enrolled. Thirty patients, including three patients at dose level 4 in the phase I part, were analyzed for efficacy. There was no complete response. Partial response and stable disease were reported in four and 16 patients, respectively (response rate 13.3 %, 95 % CI 0.0-25.5 %; disease control rate 66.6 %, 95 % CI 49.0-83.0 %). The median time to progression and overall survival was 3.0 months (95 % CI 1.8-4.2) and 10.1 months (95 % CI 6.6-13.6), respectively. Grade 3/4 toxicities included neutropenia (2 patients, 7.4 %), thrombocytopenia (1, 3.7 %), neutropenic fever (1, 3.7 %), and diarrhea (1, 3.7 %). There were no treatment-related deaths. The RP2D of the paclitaxel and irinotecan combination is paclitaxel (135 mg/m(2)) and irinotecan (160 mg/m(2)), every 3 weeks. This combination as a second-line treatment for advanced gastric cancer shows tolerable toxicity and modest efficacy. | - |
dc.language | 영어 | - |
dc.publisher | Springer Verlag | - |
dc.title | A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1007/s00280-015-2732-9 | - |
dc.citation.journaltitle | Cancer Chemotherapy and Pharmacology | - |
dc.identifier.wosid | 000354949000008 | - |
dc.identifier.scopusid | 2-s2.0-84929993674 | - |
dc.citation.endpage | 1182 | - |
dc.citation.number | 6 | - |
dc.citation.startpage | 1175 | - |
dc.citation.volume | 75 | - |
dc.identifier.sci | 000354949000008 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Lee, Keun-Wook | - |
dc.contributor.affiliatedAuthor | Kim, Jee Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Lee, Jong Seok | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | COMBINATION CHEMOTHERAPY | - |
dc.subject.keywordPlus | III TRIAL | - |
dc.subject.keywordPlus | PLUS PACLITAXEL | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | 5-FLUOROURACIL | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordAuthor | Gastric cancer | - |
dc.subject.keywordAuthor | Second line | - |
dc.subject.keywordAuthor | Paclitaxel | - |
dc.subject.keywordAuthor | Irinotecan | - |
dc.subject.keywordAuthor | Phase I/II | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.